Nexalin Technology (Nexalin Technology) Net Cash per Share : $0.22 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Nexalin Technology Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Nexalin Technology's Net Cash per Share for the quarter that ended in Mar. 2024 was $0.22.

The historical rank and industry rank for Nexalin Technology's Net Cash per Share or its related term are showing as below:

NXL' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.09 Med: 1.33 Max: 6.36
Current: 3.08

During the past 4 years, the highest Price-to-Net-Cash Ratio of Nexalin Technology was 6.36. The lowest was 1.09. And the median was 1.33.

NXL's Price-to-Net-Cash is ranked better than
70.46% of 325 companies
in the Medical Devices & Instruments industry
Industry Median: 7.17 vs NXL: 3.08

Nexalin Technology Net Cash per Share Historical Data

The historical data trend for Nexalin Technology's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nexalin Technology Net Cash per Share Chart

Nexalin Technology Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Net Cash per Share

-0.22

-0.36

0.69

0.34

Nexalin Technology Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Cash per Share	Get a 7-Day Free Trial									0.59	0.48	0.37	0.34	0.22

Competitive Comparison of Nexalin Technology's Net Cash per Share

For the Medical Devices subindustry, Nexalin Technology's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nexalin Technology's Price-to-Net-Cash Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nexalin Technology's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Nexalin Technology's Price-to-Net-Cash falls into.

Nexalin Technology Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Nexalin Technology's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

	Net Cash per Share (A: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(2.948	-	0.425	-	0)	/	7.43656
=	0.34

Nexalin Technology's Net Cash per Share for the quarter that ended in Mar. 2024 is calculated as

	Net Cash per Share (Q: Mar. 2024 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(2.144	-	0.507	-	0)	/	7.43656
=	0.22

Nexalin Technology (NAS:NXL) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

Nexalin Technology Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Nexalin Technology's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Nexalin Technology (Nexalin Technology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nexalin Technology Inc (NAS:NXL) » Definitions » Net Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

1776 Yorktown, Suite 550, Houston, TX, USA, 77056

Website

https://www.nexalin.com

Nexalin Technology Inc design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy.

Executives

Marilyn Elson	10 percent owner, officer: Ms. Elson serves as CFO	32 CAMLET COURT, ROSELAND NJ 07068
Rick Morad	director	6331 CHAGRIN RIVER ROAD, BENTLEYVILLE OH 44022
Mark White	director, officer: President/CEO	1776 YORKTOWN STREET, SUITE 550, HOUSTON TX 77056
David Owens	director, officer: Chief Medical Officer	4545 HARRIS TRAIL NW, ATLANTA GA 30327
Alan Kazden	director	3435 CONSUELO DRIVE, CALABASAS CA 91302
Leonard Osser	other: Spouse
Ben Hu	director	7021 EDGERTON ROAD, NORTH ROYALTON OH 44133